Are these 2 ASX healthcare shares the best that money can buy?

It's the healthy fundamentals that are positive.

| More on:
Businessman smiles with arms outstretched after receiving good news.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Looking to add high-quality ASX healthcare shares to your portfolio? The Australian share market is home to some of the most disruptive, innovative health companies on the planet.

ASX healthcare shares have traded flat as a group in the last three months. The S&P/ASX 200 Health Care Index (ASX: XHJ) has moved less than 1.5% since 5 March.

However, two standouts among the crowd are ResMed Inc (ASX: RMD) and CSL Ltd (ASX: CSL). Both companies are leaders in their fields and could offer attractive opportunities for growth and income, in my view.

Why ResMed is a top ASX healthcare share

ResMed is a leading player in the sleep disorder treatment market. With the rising prevalence of obstructive sleep apnoea (OSA), experts say ResMed is well-positioned for significant growth.

According to analysts at Bell Potter, the OSA market is huge. The broker says more than a billion people globally suffer from OSA, and many more remain undiagnosed.

Bell Potter reckons this massive underpenetration presents a large growth opportunity for ResMed. The broker has given the company a buy rating with a $36.00 price target. The broker cited the sleep company's competitive edge as a tailwind, which is boosted by the ongoing recall of competitor Philips' respiratory devices.

My colleague James reported that Macquarie analysts are also bullish on ResMed, with an ASX healthcare share valuation of $34.85. If correct, both price targets represent an upside potential of 15% and 12%, respectively.

ECP Asset Management likes ResMed as well. In April, portfolio manager Sam Byrnes told the Australian Financial Review that he believed the company was undervalued.

The ASX healthcare share "derated due to the frenzy" surrounding GLP-1s weight loss drugs, Byrnes said. "This raised concerns about the future of ResMed's sleep apnoea treatment".

But, even with the market's strength in 2024, ECP still finds ResMed's valuation "very appealing".

CSL remains a favourite ASX healthcare share

Biotech giant CSL has long delivered attractive capital gains and dividends for its shareholders. But it has traded flat for the last two to three years.

Despite this period of sideways movement, CSL's future looks bright, according to leading fund managers and analysts.

ECP's Sam Byrnes is positive about CSL's prospects as well. He highlights the company's volume growth and reduced cost of plasma collections as key drivers of future performance.

Byrnes – along with investment bank Macquarie – has set an eye-popping share price target of $500 over the next three years.

In the short-term, Macquarie has set a price target of $330 per share (next 12 months), driven by strong earnings growth in CSL's Behring business. This is expected to account for around 90% of CSL's profits over the next five years.

This, it says, can drive earnings higher and push the stock price to $500 per share. Analysts at Morgans and UBS are also optimistic, with the former adding CSL to its best ideas list and setting a price target of $315.40, indicating a potential upside of 11.17%.

Putting it all together, CSL could potentially trade back above $300 per share.

Two of the best?

Both ResMed and CSL could offer compelling opportunities for ASX investors. I think ResMed's growth potential in the sleep disorder market and CSL's fundamentals outlook make them two of the best ASX healthcare shares that money can buy.

It pays to remember that investing comes with a degree of risk and that past performance – or price targets – are no predictors of future performance.

Motley Fool contributor Zach Bristow has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL and ResMed. The Motley Fool Australia has positions in and has recommended ResMed. The Motley Fool Australia has recommended CSL. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Shot of a mature scientists working on a laptop in a lab.
Healthcare Shares

Telix Pharmaceuticals share price sinks on unexpected Nasdaq news

ASX 200 investors are bidding down the Telix Pharmaceuticals share price today. But why?

Read more »

Health workers shake hands and congratulate each other on good news.
Healthcare Shares

This ASX 200 healthcare stock is up 48% in a year, but one director is still buying!

A director of this ASX 200 healthcare company has just lifted his personal stake by 50%.

Read more »

A man and woman in an office look at a laptop and discuss investing, budget strategies or other financial concepts
Healthcare Shares

Why this broker just upgraded Telix shares to a buy rating

Bell Potter thinks a recent pullback has created a buying opportunity.

Read more »

A female scientist sits at her desk looking stressed out while working in an AnteoTech lab.
Healthcare Shares

Sigma share price dives 6% on Chemist Warehouse merger hurdle

The proposed merger faces ACCC concerns.

Read more »

A person wrapped in warm clothing with head, eyes and face covered by a hat, glasses and a scarf is coated in a layer of snow and ice. representing Strike Energy's trading halt today
Healthcare Shares

Why is the Telix Pharmaceuticals share price frozen today?

Telix Pharmaceuticals shares won’t be moving today.

Read more »

Shot of a mature scientists working on a laptop in a lab.
Healthcare Shares

3 ASX 300 healthcare stocks 'well positioned to outperform'

Wilsons thinks the healthcare sector could be about to outperform the broader market.

Read more »

A woman researcher holds a finger up in happiness as if making the 'number one' sign with a graphic of technological data and an orb emanating from her finger while fellow researchers work in the background.
Healthcare Shares

CSL shares can 'absolutely' head to $500: ASX expert

This expert reckons it's foolish to bet against CSL...

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

2 ASX biotech shares that could be the next Telix Pharmaceuticals

These ASX biotech shares could become the next Telix Pharmaceuticals. But how?

Read more »